A Takeda spinout builds case for its Parkinson’s drug

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 07 Oct, 12:01 UTC

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

science

Sources

• T2A Takeda spinout builds case for its Parkinson’s drugBioPharma Dive / Healthcare Dive / MedTech Dive07 Oct, 12:01